0001193125-22-207867.txt : 20220801 0001193125-22-207867.hdr.sgml : 20220801 20220801091706 ACCESSION NUMBER: 0001193125-22-207867 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cortexyme, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 221123037 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d346512d8k.htm 8-K 8-K
CORTEXYME, INC. --12-31 false 0001662774 0001662774 2022-08-01 2022-08-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2022

 

 

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38890   90-1024039

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

601 Gateway Blvd Ste 1250

South San Francisco, California

  94080
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Cortexyme, Inc.

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   CRTX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On August 1, 2022, Cortexyme, Inc. (“Cortexyme,” the “Company,” or “we”) reported that we had approximately $105 million in cash, cash equivalents and short-term investments as of June 30, 2022. These are preliminary estimates based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of June 30, 2022 or the Company’s expectations for the results of operations for the year ending December 31, 2022, or any future annual or interim period.

The information in Item 2.02 of this current report on Form 8-K is furnished and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Act of 1934, as amended, except as shall be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in such filing.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective August 1, 2022, we changed our name from “Cortexyme, Inc.” to “Quince Therapeutics, Inc.” by filing a certificate of amendment (“Certificate of Amendment”) to our Certificate of Incorporation with the Secretary of State of the State of Delaware. We also amended and restated our bylaws to reflect the change to our name, effective August 1, 2022. The Certificate of Amendment and amended and restated bylaws are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and are incorporated herein by reference.

In connection with the name change, our common stock will trade on The Nasdaq Global Select Market under the new ticker symbol “QNCX”. The new ticker symbol has become effective at the open of the market on August 1, 2022.

 

Item 8.01

Other Events.

On August 1, 2022, the Company issued a press release titled “Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit No.    Description
3.1    Certificate of Amendment to the registrant’s Certificate of Incorporation, effective August 1, 2022.
3.2    Amended and Restated Bylaws
99.1    Press Release Dated August 1, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 1, 2022

 

Quince Therapeutics, Inc.
By:  

/s/ Dirk Thye

  Dirk Thye, M.D.
  Chief Executive Officer

 

2

EX-3.1 2 d346512dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

OF

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

CORTEXYME, INC.

Cortexyme, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

A.    The Corporation was originally incorporated, and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June 20, 2012, under the name “Cortexyme, Inc.”

B.    The Certificate of Incorporation was most recently amended and restated pursuant to an Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on May 13, 2019 (the “Amended and Restated Certificate”).

C.    This Certificate of Amendment to the Amended and Restated Certificate (the “Certificate of Amendment”) was duly adopted by the Board of Directors of the Corporation without a vote of the stockholders in accordance with Sections 141 and 242 of the General Corporation Law of the State of Delaware.

Article I of the Amended and Restated Certificate is hereby amended and restated to read in its entirety as follows:

ARTICLE I

The name of the Corporation is Quince Therapeutics, Inc.”

D.    This amendment to the Amended and Restated Certificate shall be effective at 12:00 am on August 1, 2022.

IN WITNESS WHEREOF, Cortexyme, Inc. has caused this Certificate of Amendment to be signed by a duly authorized officer of the Corporation on July 29, 2022.

 

Cortexyme, Inc.
By:  

/s/ Ted Monohon

  Ted Monohon,
  Treasurer
EX-3.2 3 d346512dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

 

 

 

QUINCE THERAPEUTICS, INC.

a Delaware Corporation

AMENDED AND RESTATED BYLAWS

 

 

 


QUINCE THERAPEUTICS, INC.

a Delaware Corporation

AMENDED AND RESTATED BYLAWS

TABLE OF CONTENTS

 

         Page  

ARTICLE I: STOCKHOLDERS

     1  

Section 1.1:

  Annual Meetings      1  

Section 1.2:

  Special Meetings      1  

Section 1.3:

  Notice of Meetings      1  

Section 1.4:

  Adjournments      1  

Section 1.5:

  Quorum      2  

Section 1.6:

  Organization      2  

Section 1.7:

  Voting; Proxies      2  

Section 1.8:

  Fixing Date for Determination of Stockholders of Record      3  

Section 1.9:

  List of Stockholders Entitled to Vote      3  

Section 1.10:

  Inspectors of Elections      4  

Section 1.11:

  Notice of Stockholder Business; Nominations      5  

ARTICLE II: BOARD OF DIRECTORS

     12  

Section 2.1:

  Number; Qualifications      12  

Section 2.2:

  Election; Resignation; Removal; Vacancies      12  

Section 2.3:

  Regular Meetings      12  

Section 2.4:

  Special Meetings      12  

Section 2.5:

  Remote Meetings Permitted      12  

Section 2.6:

  Quorum; Vote Required for Action      12  

Section 2.7:

  Organization      13  

Section 2.8:

  Unanimous Action by Directors in Lieu of a Meeting      13  

Section 2.9:

  Powers      13  

Section 2.10:

  Compensation of Directors      13  

Section 2.11:

  Confidentiality      13  

ARTICLE III: COMMITTEES

     13  

Section 3.1:

  Committees      13  

Section 3.2:

  Committee Rules      14  

ARTICLE IV: OFFICERS; CHAIRPERSON; LEAD INDEPENDENT DIRECTOR

     14  

Section 4.1:

  Generally      14  

Section 4.2:

  Chief Executive Officer      14  

Section 4.3:

  Chairperson of the Board      15  

Section 4.4:

  Lead Independent Director      15  

Section 4.5:

  President      15  

Section 4.6:

  Vice President      15  

Section 4.7:

  Chief Financial Officer      15  

Section 4.8:

  Treasurer      16  

Section 4.9:

  Secretary      16  

Section 4.10:

  Delegation of Authority      16  

Section 4.11:

  Removal      16  

 

i


ARTICLE V: STOCK

     16  

Section 5.1:

  Certificates; Uncertificated Shares      16  

Section 5.2:

  Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or Uncertificated Shares      16  

Section 5.3:

  Other Regulations      17  

ARTICLE VI: INDEMNIFICATION

     17  

Section 6.1:

  Indemnification of Officers and Directors      17  

Section 6.2:

  Advance of Expenses      17  

Section 6.3:

  Non-Exclusivity of Rights      17  

Section 6.4:

  Indemnification Contracts      18  

Section 6.5:

  Right of Indemnitee to Bring Suit      18  

Section 6.6:

  Nature of Rights      18  

Section 6.7:

  Insurance      18  

ARTICLE VII: NOTICES

     19  

Section 7.1:

  Notice      19  

Section 7.2:

  Waiver of Notice      19  

ARTICLE VIII: INTERESTED DIRECTORS

     20  

Section 8.1:

  Interested Directors      20  

Section 8.2:

  Quorum      20  

ARTICLE IX: MISCELLANEOUS

     20  

Section 9.1:

  Fiscal Year      20  

Section 9.2:

  Seal      20  

Section 9.3:

  Form of Records      20  

Section 9.4:

  Reliance Upon Books and Records      20  

Section 9.5:

  Certificate of Incorporation Governs      21  

Section 9.6:

  Severability      21  

Section 9.7:

  Time Periods      21  

ARTICLE X: AMENDMENT

     21  

 

ii


QUINCE THERAPEUTICS, INC.

a Delaware Corporation

AMENDED AND RESTATED BYLAWS

ARTICLE I: STOCKHOLDERS

Section 1.1:    Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors of the Corporation (the “Board”) shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted by the Delaware General Corporation Law (the “DGCL”), or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting.

Section 1.2:    Special Meetings. Special meetings of stockholders for any purpose or purposes shall be called in the manner set forth in the Restated Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). The special meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of the meeting.

Section 1.3:    Notice of Meetings. Notice of all meetings of stockholders shall be given in writing or by electronic transmission in the manner provided by applicable law (including, without limitation, as set forth in Section 7.1.1 of these Bylaws) stating the date, time and place, if any, of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting. In the case of a special meeting, such notice shall also set forth the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Certificate of Incorporation, notice of any meeting of stockholders shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting.

Section 1.4:    Adjournments. The chairperson of the meeting shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders, annual or special, may be adjourned from time to time, and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communication (if any) by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided, however, that if the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting. To the fullest extent permitted by law, the Board may postpone, reschedule or cancel any previously scheduled special or annual meeting of the stockholders before it is to be held,


regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section 1.3 hereof or otherwise, in which case notice shall be provided to the stockholders of the new date, time and place, if any, of the meeting as provided in Section 1.3 above.

Section 1.5:    Quorum. Except as otherwise provided by applicable law, the Certificate of Incorporation or these Bylaws, at each meeting of stockholders the holders of a majority of the voting power of the shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business; provided, however, that where a separate vote by a class or classes or series of stock is required by applicable law or the Certificate of Incorporation, the holders of a majority of the voting power of the shares of such class or classes or series of the stock issued and outstanding and entitled to vote on such matter, present in person or represented by proxy at the meeting, shall constitute a quorum entitled to take action with respect to the vote on such matter. If a quorum shall fail to attend any meeting, the chairperson of the meeting or, if directed to be voted on by the chairperson of the meeting, the holders of a majority of the voting power of the shares entitled to vote who are present in person or represented by proxy at the meeting may adjourn the meeting. Shares of the Corporation’s stock belonging to the Corporation (or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation are held, directly or indirectly, by the Corporation), shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation or any other corporation to vote any shares of the Corporation’s stock held by it in a fiduciary capacity and to count such shares for purposes of determining a quorum. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum.

Section 1.6:    Organization. Meetings of stockholders shall be presided over by (a) such person as the Board may designate, or (b) in such person’s absence, the Chairperson of the Board, or (c) in the absence of such person, the Lead Independent Director, or (d) in such person’s absence, the Chief Executive Officer of the Corporation or (e) in such person’s absence, the President of the Corporation, or (f) in the absence of such person, by a Vice President. Such person shall be chairperson of the meeting and, subject to Section 1.10 of these Bylaws, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to such person to be in order. The Secretary of the Corporation shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 1.7:    Voting; Proxies. Each stockholder of record entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Except as may be required in the Certificate of Incorporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Unless otherwise provided by applicable law, rule or regulation applicable to the Corporation or its securities, the rules or regulations of any stock exchange applicable to the Corporation, the Certificate of Incorporation or these Bylaws, every matter other than the election of directors shall be decided by the affirmative vote of the holders of a majority of the voting power of the shares of stock entitled to vote on such matter that are present in person or represented by proxy at the meeting and are voted for or against the matter (or if there are

 

2


two or more classes or series of stock entitled to vote as separate classes, then in the case of each class or series, the holders of a majority of the voting power of the shares of stock of that class or series present in person or represented by proxy at the meeting voting for or against such matter).

Section 1.8:    Fixing Date for Determination of Stockholders of Record. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required by law, not be more than sixty (60), nor less than ten (10), days before the date of such meeting. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for determination of stockholders entitled to notice of or to vote at the adjourned meeting.

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60) days prior to such action. If no such record date is fixed by the Board, then the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

Section 1.9:    List of Stockholders Entitled to Vote. The Secretary shall prepare, at least ten (10) days before every meeting of stockholders, a complete list of stockholders entitled to vote at the meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date), arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least ten (10) days prior to the meeting, (a) on a reasonably accessible electronic network as permitted by applicable law (provided, that the information required to gain access to the list is provided with the notice of the meeting), or (b) during ordinary business hours, at the principal place of business of the Corporation. If the meeting is held at a location where stockholders may attend in person, the list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present at the meeting. If the meeting is held solely by means of remote communication, then the list shall be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access the list shall be provided with the notice of the meeting. Except as otherwise provided by law, the list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them.

 

3


Section 1.10:    Inspectors of Elections.

1.10.1    Applicability. Unless otherwise required by the Certificate of Incorporation or by the DGCL, the following provisions of this Section 1.10 shall apply only if and when the Corporation has a class of voting stock that is: (a) listed on a national securities exchange; (b) authorized for quotation on an interdealer quotation system of a registered national securities association; or (c) held of record by more than two thousand (2,000) stockholders. In all other cases, observance of the provisions of this Section 1.10 shall be optional, and at the discretion of the Board.

1.10.2    Appointment. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

1.10.3    Inspector’s Oath. Each inspector of election, before entering upon the discharge of such inspector’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector’s ability.

1.10.4    Duties of Inspectors. At a meeting of stockholders, the inspectors of election shall (a) ascertain the number of shares outstanding and the voting power of each share, (b) determine the shares represented at a meeting and the validity of proxies and ballots, (c) count all votes and ballots, (d) determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (e) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.

1.10.5    Opening and Closing of Polls. The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced by the chairperson of the meeting at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery of the State of Delaware, upon application by a stockholder, shall determine otherwise.

1.10.6    Determinations. In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in connection with proxies pursuant to Section 211(a)(2)b.(i) of the DGCL, or in accordance with Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section 1.10 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors’ belief that such information is accurate and reliable.

 

4


Section 1.11:    Notice of Stockholder Business; Nominations.

1.11.1 Annual Meeting of Stockholders.

(a)    Nominations of persons for election to the Board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only: (i) pursuant to the Corporation’s notice of such meeting (or any supplement thereto), (ii) by or at the direction of the Board or any committee thereof or (iii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of the notice provided for in this Section 1.11 (the “Record Stockholder”), who is entitled to vote at such meeting and who complies with the notice and other procedures set forth in this Section 1.11 in all applicable respects. For the avoidance of doubt, the foregoing clause (iii) shall be the exclusive means for a stockholder to make nominations or propose business (other than business included in the Corporation’s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the “Exchange Act”), at an annual meeting of stockholders, and such stockholder must fully comply with the notice and other procedures set forth in this Section 1.11 to make such nominations or propose business before an annual meeting.

(b)    For nominations or other business to be properly brought before an annual meeting by a Record Stockholder pursuant to Section 1.11.1(a) of these Bylaws:

(i)    the Record Stockholder must have given timely notice thereof in writing to the Secretary of the Corporation and provide any updates or supplements to such notice at the times and in the forms required by this Section 1.11;

(ii)    such other business (other than the nomination of persons for election to the Board) must otherwise be a proper matter for stockholder action;

(iii)    if the Proposing Person (as defined below) has provided the Corporation with a Solicitation Notice (as defined below), such Proposing Person must, in the case of a proposal other than the nomination of persons for election to the Board, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such Proposing Person to be sufficient to elect the nominee or nominees proposed to be nominated by such Record Stockholder, and must, in either case, have included in such materials the Solicitation Notice; and

(iv)    if no Solicitation Notice relating thereto has been timely provided pursuant to this Section 1.11, the Proposing Person proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section 1.11.

To be timely, a Record Stockholder’s notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred and twentieth (120th) day prior to the first anniversary of the preceding year’s annual meeting (except in the case of the

 

5


Corporation’s first annual meeting following its initial public offering, for which such notice shall be timely if delivered in the same time period as if such meeting were a special meeting governed by Section 1.11.2 of these Bylaws); provided, however, that in the event that the date of the annual meeting is more than thirty (30) days before, or more than sixty (60) days after, such anniversary date, notice by the Record Stockholder to be timely must be so delivered (A) no earlier than the close of business on the one hundred and twentieth (120th) day prior to such annual meeting and (B) no later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or the close of business on the tenth (10th) day following the day on which Public Announcement (as defined below) of the date of such meeting is first made by the Corporation. In no event shall an adjournment or postponement of an annual meeting for which notice has been given commence a new time period (or extend any time period) for providing the Record Stockholder’s notice. Such Record Stockholder’s notice shall set forth:

(X)    as to each person whom the Record Stockholder proposes to nominate for election or reelection as a director:

 

  (i)

the name, age, business address and residence address of such person;

 

  (ii)

the principal occupation or employment of such nominee;

 

  (iii)

the class, series and number of any shares of stock of the Corporation that are beneficially owned or owned of record by such person or any Associated Person (as defined in Section 1.11.3(c));

 

  (iv)

the date or dates such shares were acquired and the investment intent of such acquisition;

 

  (v)

all other information relating to such person that would be required to be disclosed in solicitations of proxies for election of directors in an election contest (even if an election contest is not involved), or would be otherwise required, in each case pursuant to and in accordance with Section 14(a) (or any successor provision) under the Exchange Act and the rules and regulations thereunder (including such person’s written consent to being named in the proxy statement as a nominee, to the public disclosure of information regarding or related to such person provided to the Corporation by such person or otherwise pursuant to this Section 1.11 and to serving as a director if elected); and

 

  (vi)

whether such person meets the independence requirements of the stock exchange upon which the Corporation’s Common Stock is primarily traded.

(Y)    as to any other business that the Record Stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Bylaws, the text of the proposed amendment), the reasons for conducting such business at the meeting and any material interest in such business of such Proposing Person, including any anticipated benefit to any Proposing Person therefrom; and

 

6


(Z)    as to the Proposing Person giving the notice:

 

  (i)

the current name and address of such Proposing Person, including, if applicable, their name and address as they appear on the Corporation’s stock ledger, if different;

 

  (ii)

the class or series and number of shares of stock of the Corporation that are directly or indirectly owned of record or beneficially owned by such Proposing Person, including any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future;

 

  (iii)

whether and the extent to which any derivative interest in the Corporation’s equity securities (including without limitation any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of shares of the Corporation or otherwise, and any cash-settled equity swap, total return swap, synthetic equity position or similar derivative arrangement, as well as any rights to dividends on the shares of any class or series of shares of the Corporation that are separated or separable from the underlying shares of the Corporation) or any short interest in any security of the Corporation (for purposes of this Bylaw a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any increase or decrease in the value of the subject security, including through performance-related fees) is held directly or indirectly by or for the benefit of such Proposing Person, including without limitation whether and the extent to which any ongoing hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including without limitation any short position or any borrowing or lending of shares) has been made, the effect or intent of which is to mitigate loss to or manage risk or benefit of share price changes for, or to increase or decrease the voting power of, such Proposing Person with respect to any share of stock of the Corporation;

 

  (iv)

any other material relationship between such Proposing Person, on the one hand, and the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation, on the other hand;

 

7


  (v)

any direct or indirect material interest in any material contract or agreement with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement);

 

  (vi)

any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) (or any successor provision) under the Exchange Act and the rules and regulations thereunder (the disclosures to be made pursuant to the foregoing clauses (iv) through (vi) are referred to as “Disclosable Interests”). For purposes hereof Disclosable Interests shall not include any information with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner;

 

  (vii)

such Proposing Person’s written consent to the public disclosure of information provided to the Corporation pursuant to this Section 1.11;

 

  (viii)

a complete written description of any agreement, arrangement or understanding (whether oral or in writing) (including any knowledge that another person or entity is Acting in Concert (as defined in Section 1.11.3(c)) with such Proposing Person) between or among such Proposing Person, any of its respective affiliates or associates and any other person Acting in Concert with any of the foregoing persons;

 

  (ix)

as to each person whom such Proposing Person proposes to nominate for election or re-election as a director, any agreement, arrangement or understanding of such person with any other person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director known to such Proposing Person after reasonable inquiry;

 

  (x)

a representation that the Record Stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination;

 

  (xi)

a representation whether such Proposing Person intends (or is part of a group that intends) to deliver a proxy statement or form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation’s voting shares required under applicable law to

 

8


  carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent being a “Solicitation Notice”); and

 

  (xii)

any proxy, contract, arrangement, or relationship pursuant to which the Proposing Person has a right to vote, directly or indirectly, any shares of any security of the Corporation;

A stockholder providing written notice required by this Section 1.11 will update and supplement such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i) the record date for the meeting and (ii) the close of business on the fifth (5th) business day prior to the meeting and, in the event of any adjournment or postponement thereof, the close of business on the fifth (5th) business day prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i) of the foregoing sentence, such update and supplement will be received by the Secretary of the Corporation at the principal executive office of the Corporation not later than five (5) business days after the record date for the meeting, and in the case of an update and supplement pursuant to clause (ii) of the foregoing sentence, such update and supplement will be received by the Secretary of the Corporation at the principal executive office of the Corporation not later than two (2) business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two (2) business days prior to such adjourned or postponed meeting.

(c)    Notwithstanding anything in the second sentence of Section 1.11.1(b) of these Bylaws to the contrary, in the event that the number of directors to be elected to the Board is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board at least one hundred (100) days prior to the first anniversary of the preceding year’s annual meeting (or, if the annual meeting is held more than thirty (30) days before or sixty (60) days after such anniversary date, at least one hundred (100) days prior to such annual meeting), a stockholder’s notice required by this Section 1.11 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary of the Corporation at the principal executive office of the Corporation no later than the close of business on the tenth (10th) day following the day on which such Public Announcement is first made by the Corporation.

(d)    Notwithstanding anything in Section 1.11 or any other provision of the Bylaws to the contrary, any person who has been determined by a majority of the Whole Board to have violated Section 2.11 of these Bylaws or a Board Confidentiality Policy (as defined below) while serving as a director of the Corporation in the preceding five (5) years shall be ineligible to be nominated or serve as a member of the Board, absent a prior waiver for such nomination or service approved by two-thirds of the Whole Board.

1.11.2    Special Meetings of Stockholders. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of such meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of such meeting (a) by or at the direction of the Board or any committee thereof or (b) provided that the Board has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice of the special meeting, who shall be entitled to vote at the meeting and who

 

9


complies with the notice and other procedures set forth in this Section 1.11 in all applicable respects. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation’s notice of meeting, if the stockholder’s notice required by Section 1.11.1(b) of these Bylaws shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation (i) no earlier than the one hundred twentieth (120th) day prior to such special meeting and (ii) no later than the close of business on the later of the ninetieth (90th) day prior to such special meeting or the tenth (10th) day following the day on which Public Announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting

1.11.3    General.

(a)    Only such persons who are nominated in accordance with the procedures set forth in this Section 1.11 shall be eligible to be elected at a meeting of stockholders and serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 1.11. Except as otherwise provided by law or these Bylaws, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any other business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 1.11 and, if any proposed nomination or business is not in compliance herewith, to declare that such defective proposal or nomination shall be disregarded. Notwithstanding the foregoing provisions of this Section 1.11, unless otherwise required by law, if the stockholder (or a Qualified Representative of the stockholder (as defined below)) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation.

(b)    Notwithstanding the foregoing provisions of this Section 1.11, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 1.11 shall be deemed to affect any rights of (a) stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act or (b) the holders of any series of Preferred Stock to elect directors pursuant to any applicable provisions of the Certificate of Incorporation.

(c)    For purposes of this Section 1.11 the following definitions shall apply:

(i)    a person shall be deemed to be “Acting in Concert” with another person if such person knowingly acts (whether or not pursuant to an express agreement, arrangement or understanding) in concert with, or toward a common goal relating to the management, governance or control of the Corporation in substantial parallel with, such other person where (1) each person is conscious of the other person’s conduct or intent and this awareness is an element in their decision-making processes and (2) at least one additional factor suggests that such persons intend to act in concert or in substantial parallel, which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions or making or soliciting invitations to act in concert or in substantial parallel; provided, that a person shall not be deemed to be Acting in Concert with any other person solely as a result of the solicitation or receipt of revocable proxies or consents from such other person in response

 

10


to a solicitation made pursuant to, and in accordance with, Section 14(a) (or any successor provision) of the Exchange Act by way of a proxy or consent solicitation statement filed on Schedule 14A. A person Acting in Concert with another person shall be deemed to be Acting in Concert with any third party who is also Acting in Concert with such other person;

(ii)     “Associated Person” shall mean with respect to any subject stockholder or other person (including any proposed nominee) (1) any person directly or indirectly controlling, controlled by or under common control with such stockholder or other person, (2) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such stockholder or other person, (3) any associate (as defined in Rule 405 under the Securities Act of 1933, as amended), of such stockholder or other person, and (4) any person directly or indirectly controlling, controlled by or under common control or Acting in Concert with any such Associated Person;

(iii)     “Proposing Person” shall mean (1) the stockholder providing the notice of business proposed to be brought before an annual meeting or nomination of persons for election to the Board at a stockholder meeting, (2) the beneficial owner or beneficial owners, if different, on whose behalf the notice of business proposed to be brought before the annual meeting or nomination of persons for election to the Board at a stockholder meeting is made, and (3) any Associated Person on whose behalf the notice of business proposed to be brought before the annual meeting or nomination of persons for election to the Board at a stockholder meeting is made;

(iv)    “Public Announcement” shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act; and

(v)    to be considered a “Qualified Representative” of a stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as a proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction thereof, at the annual meeting; provided, however, that if the stockholder is (1) a general or limited partnership, any general partner or person who functions as a general partner of the general or limited partnership or who controls the general or limited partnership shall be deemed a Qualified Representative, (2) a corporation or a limited liability company, any officer or person who functions as the substantial equivalent of an officer of the corporation or limited liability company or any officer, director, general partner or person who functions as an officer, director or general partner of any entity ultimately in control of the corporation or limited liability company shall be deemed a Qualified Representative or (z) a trust, any trustee of such trust shall be deemed a Qualified Representative. The Secretary of the Corporation, or any other person who shall be appointed to serve as secretary of the meeting, may require, on behalf of the Corporation, reasonable and appropriate documentation to verify the status of a person purporting to be a “Qualified Representative” for purposes hereof.

 

11


ARTICLE II: BOARD OF DIRECTORS

Section 2.1:    Number; Qualifications. The total number of directors constituting the Board (the “Whole Board”) shall be fixed from time to time in the manner set forth in the Certificate of Incorporation. No decrease in the authorized number of directors constituting the Whole Board shall shorten the term of any incumbent director. Directors need not be stockholders of the Corporation.

Section 2.2:    Election; Resignation; Removal; Vacancies. Election of directors need not be by written ballot. Unless otherwise provided by the Certificate of Incorporation and subject to the special rights of holders of any series of Preferred Stock to elect directors, the Board shall be divided into three classes, designated as Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one-third of the Whole Board. Each director shall hold office until the annual meeting at which such director’s term expires and until such director’s successor is elected and qualified or until such director’s earlier death, resignation, disqualification or removal. Any director may resign by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairperson of the Board, the Chief Executive Officer, or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at a later time or upon the happening of an event. Subject to the special rights of holders of any series of Preferred Stock to elect directors, directors may be removed only as provided by the Certificate of Incorporation and applicable law. All vacancies occurring on the Board and any newly created directorships resulting from any increase in the authorized number of directors shall be filled in the manner set forth in the Certificate of Incorporation.

Section 2.3:    Regular Meetings. Regular meetings of the Board may be held at such places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board.

Section 2.4:    Special Meetings. Special meetings of the Board may be called by the Chairperson of the Board, the Chief Executive Officer, the Lead Independent Director or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the notice is mailed, or at least twenty-four (24) hours before the meeting if such notice is given by telephone, hand delivery, telegram, telex, mailgram, facsimile, electronic mail or other means of electronic transmission. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

Section 2.5:    Remote Meetings Permitted. Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.

Section 2.6:    Quorum; Vote Required for Action. At all meetings of the Board, a majority of the Whole Board shall constitute a quorum for the transaction of business. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time without further notice thereof. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board.

 

12


Section 2.7:    Organization. Meetings of the Board shall be presided over by (a) the Chairperson of the Board, or (b) in the absence of such person, the Lead Independent Director, or (c) in such person’s absence, the Chief Executive Officer, or (d) in such person’s absence, by a chairperson chosen by the Board at the meeting. The Secretary shall act as secretary of the meeting, but in such person’s absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

Section 2.8:    Unanimous Action by Directors in Lieu of a Meeting. Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee, as applicable. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

Section 2.9:    Powers. Except as otherwise provided by the Certificate of Incorporation or the DGCL, the business and affairs of the Corporation shall be managed by or under the direction of the Board.

Section 2.10:    Compensation of Directors. Members of the Board, as such, may receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board.

Section 2.11:    Confidentiality. Each director shall maintain the confidentiality of, and shall not share with any third party person or entity (including third parties that originally sponsored, nominated or designated such director (the “Sponsoring Party”)), any non-public information learned in their capacities as directors, including communications among Board members in their capacities as directors. The Board may adopt a board confidentiality policy further implementing and interpreting this bylaw (a “Board Confidentiality Policy”). All directors are required to comply with this bylaw and any such Board Confidentiality Policy unless such director or Sponsoring Party for such director has entered into a specific written agreement with the Corporation, in either case as approved by the Board, providing otherwise with respect to such confidential information.

ARTICLE III:    COMMITTEES

Section 3.1:    Committees. The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it.; but no such committee shall have the power or authority in reference to the following matters: (a) approving, adopting or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or (b) adopting, amending or repealing any bylaw of the Corporation.

 

13


Section 3.2:    Committee Rules. Each committee shall keep records of its proceedings and make such reports as the Board may from time to time request. Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these Bylaws. Except as otherwise provided in the Certificate of Incorporation, these Bylaws or the resolution of the Board designating the committee, any committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and may delegate to any such subcommittee any or all of the powers and authority of the committee.

ARTICLE IV: OFFICERS; CHAIRPERSON; LEAD INDEPENDENT DIRECTOR

Section 4.1:    Generally. The officers of the Corporation shall consist of a Chief Executive Officer (who may be the Chairperson of the Board or the President), a President, a Secretary and a Treasurer and may consist of such other officers, including, without limitation, a Chief Financial Officer and one or more Vice Presidents, as may from time to time be appointed by the Board. All officers shall be elected by the Board; provided, however, that the Board may empower the Chief Executive Officer of the Corporation to appoint any officer other than the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Except as otherwise provided by law, by the Certificate of Incorporation or these Bylaws, each officer shall hold office until such officer’s successor is duly elected and qualified or until such officer’s earlier resignation, death, disqualification or removal. Any number of offices may be held by the same person. Any officer may resign by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairperson of the Board, the Chief Executive Officer or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board and the Board may, in its discretion, leave unfilled, for such period as it may determine, any offices. Each such successor shall hold office for the unexpired term of such officer’s predecessor and until a successor is duly elected and qualified or until such officer’s earlier resignation, death, disqualification or removal.

Section 4.2:    Chief Executive Officer. Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are:

(a)    to act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business and affairs of the Corporation;

(b)    subject to Article I, Section 1.6 of these Bylaws, to preside at all meetings of the stockholders;

(c)    subject to Article I, Section 1.2 of these Bylaws, to call special meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as the Chief Executive Officer shall deem proper;

(d)    to affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation;

 

14


(e)    to sign certificates for shares of stock of the Corporation (if any); and

(f)    subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation.

The person holding the office of President shall be the Chief Executive Officer of the Corporation unless the Board shall designate another officer to be the Chief Executive Officer.

Section 4.3:    Chairperson of the Board. Subject to the provisions of Section 2.7 of these Bylaws, the Chairperson of the Board shall have the power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe.

Section 4.4:    Lead Independent Director. The Board may, in its discretion, elect a lead independent director from among its members that are Independent Directors (as defined below) (such director, the “Lead Independent Director”). He or she shall preside at all meetings at which the Chairperson of the Board is not present and shall exercise such other powers and duties as may from time to time be assigned to him or her by the Board or as prescribed by these Bylaws. For purposes of these Bylaws, “Independent Director” has the meaning ascribed to such term under the rules of the exchange upon which the Corporation’s Class A Common Stock is primarily traded.

Section 4.5:    President. The person holding the office of Chief Executive Officer shall be the President of the Corporation unless the Board shall have designated one individual as the President and a different individual as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board, and subject to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board, and/or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are delegated to the President by the Board.

Section 4.6:    Vice President. Each Vice President shall have all such powers and duties as are commonly incident to the office of Vice President or that are delegated to him or her by the Board or the Chief Executive Officer. A Vice President may be designated by the Board to perform the duties and exercise the powers of the Chief Executive Officer or President in the event of the Chief Executive Officer’s or President’s absence or disability.

Section 4.7:    Chief Financial Officer. The person holding the office of Chief Financial Officer shall be the Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer, or as the Board may from time to time prescribe.

 

15


Section 4.8:    Treasurer. The person holding the office of Treasurer shall have custody of all monies and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe.

Section 4.9:    Secretary. The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board. The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe.

Section 4.10:    Delegation of Authority. The Board may from time to time delegate the powers or duties of any officer of the Corporation to any other officers or agents of the Corporation, notwithstanding any provision hereof.

Section 4.11:    Removal. Any officer of the Corporation shall serve at the pleasure of the Board and may be removed at any time, with or without cause, by the Board; provided that if the Board has empowered the Chief Executive Officer to appoint any officer of the Corporation, then such officer may also be removed by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

ARTICLE V: STOCK

Section 5.1:    Certificates; Uncertificated Shares. The shares of capital stock of the Corporation shall be uncertificated shares; provided, however, that the resolution of the Board that the shares of capital stock of the Corporation shall be uncertificated shares shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation (or the transfer agent or registrar, as the case may be). Notwithstanding the foregoing, the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be certificated shares. Every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of the Corporation, by the Chairperson or Vice-Chairperson of the Board, the Chief Executive Officer or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue.

Section 5.2:    Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or Uncertificated Shares. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to agree to indemnify the Corporation and/or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.

 

16


Section 5.3:    Other Regulations. Subject to applicable law, the Certificate of Incorporation and these Bylaws, the issue, transfer, conversion and registration of shares represented by certificates and of uncertificated shares shall be governed by such other regulations as the Board may establish.

ARTICLE VI: INDEMNIFICATION

Section 6.1:    Indemnification of Officers and Directors. Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, legislative or any other type whatsoever (a “Proceeding”), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a director or officer of the Corporation or, while serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (for purposes of this Article VI, an “Indemnitee”), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith, provided such Indemnitee acted in good faith and in a manner that the Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful. Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer of the Corporation and shall inure to the benefit of such Indemnitees’ heirs, executors and administrators. Notwithstanding the foregoing, subject to Section 6.5 of these Bylaws, the Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is authorized by an agreement approved by the Board.

Section 6.2:    Advance of Expenses. Except as otherwise provided in a written indemnification contract between the Corporation and an Indemnitee, the Corporation shall pay all expenses (including attorneys’ fees) incurred by an Indemnitee in defending any Proceeding in advance of its final disposition; provided, however, that if the DGCL then so requires, the advancement of such expenses shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay such amounts if it shall ultimately be determined that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise.

Section 6.3:     Non-Exclusivity of Rights. The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.

 

17


Section 6.4:    Indemnification Contracts. The Board is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification or advancement rights to such person. Such rights may be greater than those provided in this Article VI.

Section 6.5:    Right of Indemnitee to Bring Suit. The following shall apply to the extent not in conflict with any indemnification contract provided for in Section 6.4 of these Bylaws.

6.5.1    Right to Bring Suit. If a claim under Section 6.1 or 6.2 of these Bylaws is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid, to the fullest extent permitted by law, the expense of prosecuting or defending such suit. In any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that the Indemnitee has not met any applicable standard of conduct which makes it permissible under the DGCL (or other applicable law) for the Corporation to indemnify the Indemnitee for the amount claimed.

6.5.2    Effect of Determination. Neither the absence of a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit.

6.5.3    Burden of Proof. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI, or otherwise, shall be on the Corporation.

Section 6.6:    Nature of Rights. The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators. Any amendment, repeal or modification of any provision of this Article VI that adversely affects any right of an Indemnitee or an Indemnitee’s successors shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI with respect to any Proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, repeal or modification.

Section 6.7:    Insurance. The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.

 

18


ARTICLE VII: NOTICES

Section 7.1:    Notice.

7.1.1    Form and Delivery. Except as otherwise specifically required in these Bylaws (including, without limitation, Section 7.1.2 of these Bylaws) or by applicable law, all notices required to be given pursuant to these Bylaws shall be in writing and may (a) in every instance in connection with any delivery to a member of the Board, be effectively given by hand delivery (including use of a delivery service), by depositing such notice in the mail, postage prepaid, or by sending such notice by overnight express courier, facsimile, electronic mail or other form of electronic transmission and (b) be effectively delivered to a stockholder when given by hand delivery, by depositing such notice in the mail, postage prepaid or, if specifically consented to by the stockholder as described in Section 7.1.2 of these Bylaws by sending such notice by facsimile, electronic mail or other form of electronic transmission. Any such notice shall be addressed to the person to whom notice is to be given at such person’s address as it appears on the records of the Corporation. The notice shall be deemed given: (a) in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person; (b) in the case of delivery by mail, upon deposit in the mail; (c) in the case of delivery by overnight express courier, when dispatched; and (d) in the case of delivery via facsimile, electronic mail or other form of electronic transmission, at the time provided in Section 7.1.2 of these Bylaws.

7.1.2    Electronic Transmission. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation, or these Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given in accordance with Section 232 of the DGCL. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if (a) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (b) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; provided, however, that the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given pursuant to this Section 7.1.2 shall be deemed given: (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of such posting and the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed to the stockholder.

7.1.3    Affidavit of Giving Notice. An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given in writing or by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

Section 7.2:    Waiver of Notice. Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the

 

19


person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.

ARTICLE VIII: INTERESTED DIRECTORS

Section 8.1:    Interested Directors. No contract or transaction between the Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because such director’s or officer’s votes are counted for such purpose, if: (a) the material facts as to such director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (b) the material facts as to such director’s or officer’s relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (c) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders.

Section 8.2:    Quorum. Interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.

ARTICLE IX: MISCELLANEOUS

Section 9.1:    Fiscal Year. The fiscal year of the Corporation shall be determined by resolution of the Board.

Section 9.2:    Seal. The Board may provide for a corporate seal, which may have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board.

Section 9.3:    Form of Records. Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of any other information storage device or method, electronic or otherwise, provided, that the records so kept can be converted into clearly legible paper form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL.

Section 9.4:    Reliance Upon Books and Records. A member of the Board, or a member of any committee designated by the Board shall, in the performance of such person’s duties, be fully protected in relying in good faith upon the books and records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

 

20


Section 9.5:    Certificate of Incorporation Governs. In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

Section 9.6:    Severability. If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.

Section 9.7:    Time Periods. In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.

ARTICLE X: AMENDMENT

Notwithstanding any other provision of these Bylaws, any alteration, amendment or repeal of these Bylaws, and any adoption of new Bylaws, shall require the approval of the Board or the stockholders of the Corporation as expressly provided in the Certificate of Incorporation.

* * * * *

 

21

EX-99.1 4 d346512dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

NEWS RELEASE   LOGO

Quince Therapeutics Details Strategic Growth Plan with

Launch of New Corporate Name

Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases

Highly differentiated bone-targeting drug platform and lead precision bone growth molecule NOV004 to address underserved therapeutic areas with major, unmet medical needs

Pursuing strategic development pipeline expansion through opportunistic in-licensing and acquisition of clinical-stage assets targeting debilitating and rare diseases

Strong cash position of approximately $105 million provides

operating runway into the second half of 2025

Trading on Nasdaq to initiate under new ticker symbol “QNCX”

SOUTH SAN FRANCISCO, Calif. – August 1, 2022 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today. The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision bone growth molecule, NOV004, to address major, unmet medical needs across multiple skeletal therapeutic indications. Quince also announced that the company plans to pursue the strategic expansion of its development pipeline through opportunistic in-licensing and acquisition of clinical-stage assets targeting debilitating and rare diseases, in addition to disclosing the company’s intent to out-license its legacy neuroscience and antiviral assets.

Dirk Thye, M.D., Quince’s chief executive officer, said, “We are eager and enthusiastic about launching Quince Therapeutics and introducing our new corporate strategy focused on the development and acquisition of innovative precision therapeutics for patients suffering from debilitating and rare diseases. Our proprietary bone-targeting drug platform and novel lead molecule, NOV004, are positioned to establish Quince as an important new leader in underserved therapeutic areas with major and unmet medical needs in a setting of historical underinvestment and few competitive companies. Our core technology is based on more than 10 years of extensive preclinical research and can be applied to a broad variety of skeletal diseases and indications as we look to expand our proprietary pipeline.

“We also benefit from a highly experienced management team with a long track record of drug development success and value creation. This team is empowered by a cash runway extending into the second half of 2025, providing us near-term financial security in a period of economic uncertainty in the biotech sector. This strong financial position is expected to enable us to not only fully fund reaching NOV004’s human proof of concept clinical development milestone, but also allow Quince to pursue strategic in-licensing and acquisition of additional clinical-stage assets. We intend to aggressively leverage the advantages of our strong team and balance sheet to build a highly impactful and valuable company,” Thye concluded.


Quince Therapeutics

Page 2

 

Strategic Growth Plan Highlights

Today, Quince embarks on a fundamental shift in its strategic growth plan that now centers on advancing innovative precision therapeutics targeting debilitating and rare diseases. Key highlights of the company’s strategic growth plan include:

Addressing major, unmet medical needs across multiple skeletal therapeutic indications

 

   

Major, unmet medical needs have been estimated to include more than 18 million fractures in the U.S. each year that have led to more than $50 billion in direct medical costs.

 

   

Underserved bone fracture opportunity compounded by a growing aging population experiencing higher rate of life-threatening fractures.

 

   

No treatments currently approved for lead indication, osteogenesis imperfecta, which has been estimated to affect as many as 50,000 people in the U.S. alone.

 

   

Positioned as a lead innovator in underserved therapeutic areas with few competitive companies.

 

   

Discovery pipeline positioned for rapid expansion across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases.

 

   

Strong and well-protected intellectual property with robust portfolio of precision bone therapeutics.

Highly differentiated bone-targeting drug platform and broad applicability of lead molecule NOV004

 

   

Proprietary drug-targeting technology designed to enable precise delivery of small molecules, peptides, or large molecules directly to the site of bone fracture and disease.

 

   

Development pathway de-risked by more than 10 years of extensive preclinical studies demonstrating that concentrated drug-targeting promotes more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

 

   

Lead precision bone growth molecule NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, resulting in rapid increases in bone density, strength, and healing as demonstrated in preclinical studies.

 

   

NOV004 expected to enter Phase 1 clinical studies in 2023.

 

   

Future development plans include progression of NOV004 to Phase 2 clinical study to evaluate safety and efficacy for the treatment of planned lead indication, osteogenesis imperfecta.

Strategic pipeline expansion through opportunistic in-licensing and acquisition of clinical-stage assets

 

   

Proactively evaluating potentially actionable clinical-stage assets targeting debilitating and rare diseases for in-licensing and acquisition.

 

   

Potential asset targets must have compelling clinical data and commercial opportunity and offer clear operational synergy and value creation.

 

   

Intend to be opportunistic and disciplined in approach with ability to be selective and competitive in evolving biotech environment.


Quince Therapeutics

Page 3

 

Strong cash position expected to fund operations and clinical activities into the second half of 2025

 

   

Strong cash position of approximately $105 million in cash, equivalents, and marketable securities as of June 30, 2022 is expected to fund capital and operating expenditures into the second half of 2025.

 

   

Expect to fully fund achievement of lead molecule NOV004’s human proof of concept clinical development milestone.

 

   

Corporate restructuring in first half of 2022 optimized organization for operating efficiency.

Out-licensing legacy neuroscience and antiviral assets

 

   

Seeking to out-license capital-intensive legacy neuroscience and antiviral assets, including COR588, COR388, COR852, and COR803.

 

   

Lysine gingipain inhibitor COR588 is Phase 2 ready for further evaluation in Alzheimer’s disease and other P. gingivalis associated diseases.

 

   

Antiviral 3CLpro irreversible inhibitor COR803 for coronavirus infection positioned at IND-enabling preclinical study phase.

 

   

Out-licensing effort to identify partners already underway with goal of concluding the process before the end of 2022.

Initiates Nasdaq Trading Under New Ticker Symbol “QNCX”

Quince’s ticker symbol on the Nasdaq Stock Market will begin to trade under “QNCX” effective at the open of market trading today, Monday, August 1, 2022. The corporate name change to Quince Therapeutics, Inc. does not affect the rights of the company’s stockholders with respect to the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

Management to Participate at Upcoming Investor Conference

Quince’s chief executive officer Dirk Thye, M.D., will present at the Canaccord Genuity 42nd Annual Growth Conference taking place on Thursday, August 11, 2022 beginning at 2:30 p.m. Eastern Time. A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Quince’s investor website at https://quincetx.com/. The webcast will be archived at that location for 90 days.

About Quince Therapeutics

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.


Quince Therapeutics

Page 4

 

Forward-looking Statements

Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, clinical development and strategic development path for NOV004; cash runway and the ability to fund clinical development milestones; the company’s plans to pursue the strategic expansion of its development pipeline, its intent to out-license its legacy neuroscience and antiviral assets, the strategic growth plan, the FDA and clinical development plans and timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company’s product candidate and discovery pipeline; and statements about its ability to obtain, and the timing relating to, further development and/or out-licensing of its legacy neuroscience and antiviral assets, regulatory submissions, and related response and decisions. Forward-looking statements are based on Quince Therapeutic’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.

 

Quince Therapeutics Contact:

 

Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

EX-101.SCH 5 crtx-20220801.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 crtx-20220801_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Information, Former Legal or Registered Name Entity Information, Former Legal or Registered Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Current Fiscal Year End Date Current Fiscal Year End Date Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 7 crtx-20220801_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g346512g0801081805238.jpg GRAPHIC begin 644 g346512g0801081805238.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^LS6M?TW MP_:?:-0N!&#]Q!R[GT [TSQ'KUMX;T2?4KGD(-L:9Y=ST45\^ZGK%WKNH27U M]*9)G/ [(.P ["HG/E./%8KV*LMSOM2^+MX[LNF:?%%'V>X)9C[X& /UK*3X MH^)5<,SVCK_=,.!^AK%T/PIK'B#YK&V_<@X,TAVI^![_ (5T4OPFUQ(BR75G M(X'W,L,_CBLKS>IYZGBZGO*YVGA+QR=>LY7O+=(IHGVMY1)&".#@_C^5=C'( MDJ!T8,IZ$5X%I[ZCX+UX+J5K)%'(-DJ]0R_WE/0XKU;2]35 D\,@DMI1G*G( M(]1[UPSQL\/6Y:OP/9]CLPV)DURU-T=312*P90RG((R#2UZQZ 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'AGQKUYI/$-C MHR/^[MH?/D7_ &V) _(#]:Y_P'HI\3^(X;)R?LR*9;@C^X.WXD@51^,4S1_% M/40W3R8"OTV#^N:ZSX"31OK&L*2/,^SQE?IN.?Z5DXWEJ>?4HJ=;WCW"WMX; M6W2""-8XHQM5%& !4M%9NN:_IGAS3S?:K=);P;MH+=6/H!W-:GH#/$&@VGB' M2I;*Y09(S')CF-NQ%>%V6L:IX9O9[16_U4C)+"_*Y!P<>E>\Z-K>G>(-.2_T MRY2XMG) 9>Q'4'T->&^.8C'XTU0^4Z*\V5++@-P,D>O-<^(IQG&TE<\S,(\J M52.YZUX&\1#Q#HTCF+RI+>3RV7.>P(/ZUU%>9?!W=]DU<_P^;'CZX/\ ]:O3 M:TI)1@DNAUX6;G1BV(2 "2< =36)>>,/#]C(8Y]4@#@X*J=W\J\V\>^-+G4M M1ETG3I62SB;RW,9YF?H?PSQ2Z/\ "K4;ZV6XO[E;3>,B,+N8?6AS;=HF$L7. M4W"C&]CTZP\3Z+J;A+34H)'/1-V"?P-:U>(>(?ASJ>@VS7MM*+J"/YG*#:Z# MUQ71_#CQI/>SKHFI2F20KFVF8\MCJI_#I0IN]I%4\5+G]G55FST&_P!3L=,C M62^NHK=7.%,C8R:DM+RWOK9;BUF2:%_NNAR#7G/QB_X]-(_ZZR?R%;7PN_Y$ MF'_KM+_Z%3YO>L:1KMUW2MLCLZSAKVDF_P#L(U"W-UOV>5OYW>GUK1KP"#_D MIB'_ *B__M2B4K!B*[IPMFN+J9(85^\[G %1V&IV.IQM)8W45 MPJ':QC;.#7+_ !1_Y$F;_KM%_P"A5A_!W_4:Q_OQ?R:CF]ZP2KM5U2MN>@W6 MLZ;8WD5I=7L,-Q-]R-VP3VJ]7B7Q5_Y')?\ KUC_ )M76?#OQG_:<"Z1J,O^ MFQ+^ZD8_ZU1V_P!X4*?O69$,6G6=*6G8[V::*V@>::18XD&YG8X %5;#6-.U M1G6QO(;AD +!&R169XY_Y$C5_P#K@?YBO/\ X0_\A_4/^O4?^A"ARM)(NI7< M:T:=MSV&L[4-=TO2N+Z^A@;^ZS<_EUKF_B#XO?P]9QV=DP%_<@D-_P \TZ;O MKZ5YUX>\':MXN=[QY2D!8[KF;+%SWQZT2GK9$5L4XS]G35V>MVWC7PY=2>7' MJL&XG #97/YUO(ZR('1@RD9!!R#7D>H?".\AMS)97Z3R*,^6Z[<_0U>^&D?B M.UU&XM+J*5--C!#K/_"_;;_6DI2O9H5/$55-0JQW['?7NO:5IT_D7E_!#+C= ML=L'%5_^$M\/_P#06M?^^Z\C^)_'C>Z.,X@B_P#0:W;3X2BZLX+C^U"OFQJ^ M/+Z9&:.>3=DB/K-:524(1O8]!B\4:%/,D4>J6S2.P55#]2:UZ\RM?A(L%Y!. M^J,RQ2*Y C )PYU4959)^T5CYY_:'T*2VUG3/$42?N9XOLLS#LZD ME<_4$_\ ?-<+X \7OX3\46VIX+V^#%<(.K1GK^(X/X5]4^)_#MEXK\/76CWZ MYAG7AAU1AT8>X-?'WBCPMJW@K6I-.U.(A0?W4P'R2KV(--HJ<+ZH^S=-U.SU M>PBOK"X2>WE7U/4_$MI8ZW);+:S@QAU3;AS]W)],\?C2YB M562=F/L=:M/@GH:Z/=EM1U>\D-U)%$<)$I 4F?#S0IM#\.,ERNVXGG=W'L#M M'Z#/XUT>IRO!I5Y,GWXX'9?J%)K@_#WQF\.:[J<=@Z3V4LK;8FG VL3T&1T- M>ARQK-$\3C*.I5AZ@TDK*Q$*:A#DB>"_#VUBOO&M@+@!PH>;![L%)'Z\U[[7 MSTZ7G@CQ@#L/F6CZU:K-;WD:L1\TU0:1X_$=J?EMM2V1X]/,QC\N*]=\2>.-+T M*RD,<\=Q>$$1PHV>?4^@KR_P-I-QK_B^&YD!:."7[3<2$<%LY _$T3=VDA8R M2G4A"&]SJ_C%_P >FD?]=)/Y"MKX7_\ (DP_]=I?_0JI_%G3I+KP_;7L8+"T MFRX'96&,_GBLOX8>*+*TL)-&O9EA<2F2%G. P/49]<_SHVGJ5=0QCSZOXGTK1K&2YGNXF(7*1HP+.>P%>.>#K:?7/'EM.5Z7# M7YZ1\4/^1)F_Z[1?^A5A_!W_ %&L?[\7\FK< M^*'_ "),W_7:+_T*L/X._P"HUC_?B_DU#_B%3_WV/I_F8/Q6_P"1P_[=$_FU M5==\,W.A6.EZ]I[.()H8I&=3S#*5!_(FK/Q6_P"1P_[=$_FU>JZ/:P7W@[3[ M6YC62&6RC5U8<$;!2Y>:3,%15:M477H*O#EWX2U22*-W-GXK?\ A#_R']0_ MZ]1_Z$*2;PV@_P R:]LT>TAL=&L[ M6!0(XX5 QWXZUY9\5]$D@UB/5T0FWN4$&!) M^@K%\,^/K#Q)J4MBD,D$PRT0?_EHH[^QK3F5['>ZL%)1;U9YO\3AGQQ=#UAB M_P#0:T+;XH:S;VL,":?"5C14!PW( Q6=\3_^1VN_^N$?_H->M:9+I TFSWM9 M[O(3.=N<[16*3.?I78 MU3ANM.5MD$ULI8]$91D_A5RMEL>G234;2=V%9FN^'M*\2Z>UCJUG'>TFA:P8D/(ANESC_@0_PK,M?@/XC64"34;%4S]X%C M_2OH:BDTF1*G&6Y@>%-%U30],6UU+5VU%E ",R8VCTSU/XUXS\?X[H>*M,DD M#?9#9E8C_#OW'=^.-M?0M96O^'=+\3:<;'5K59X<[ESPR'U![&F5%)*Q\;!7 M=E2(,9&("!>I;MCWS7VIIBSII5FMT&=1\-SQ1W\:CSEW)(ARI]1 MGUKU_P"'ESI,_AF,:9$L,B'%RF^>U:_B33=,U/1)X]6 %K$IE:3.#' MCG<#7&^%;KP+H^L8TG7C+=7 6'R6ER"2?ER,=?2I4'&6AA2PLJ-:\=8_B>B3 MP17,$D$\:R12*5=&&00:\NUKX32&=I='ND\ICD0S=5^AKTU[^UCU"*P:=!=2 MQM*D1/S,JD D#T!8?G2+?VKZC)IZSH;N.)9GBS\P1B0#CT)4_E52BGN=-6A" MJK31Y#;?"C7)90+B>VA3NVXL:]*\,^%;'PQ9M%;9DGD_UL[#YF_P'M2:CXT\ M/:3J$EC?:I!#=1 %XB>5R,C/U%7IM;TVWT3^V9KN--/\L2^>QPNT]#^HHC!+ M8FEA:5)WBM2EXOT*;Q%X>ET^"5(I&=75GZ<'-9W@3PG<^%K>]6ZGCE>X=2/+ MS@!0?7ZUK:5XJT/6[AK?3M2MYYU7<8U;YL>N/2M"^OK73+*2\O9X[>VB&7ED M;"KSCDT^57N6Z,'453J<-XU\ WOB36EO[2ZAC7R1&RR9R""?3ZUV^F6AL-*M M+,L',$*1EAWP ,U:ZC(KGCXY\,K?O8MK-JMPDIA96?&'!P5SZYXH44G<(480 MFYK=FAKFBVFOZ7+87:Y5QE7'5&[$5RW@;P3>^&-3O;FZN(I5DC$4>S.2,YR: MZS5=8T_1++[9J5U';6^X)OXJ MN'IU?C1Y+;_"C7)90)YK:).[;RQKT7POX-T_PQ&SQ9FNW&'G<_O8[.UUBWEN)'"+&IY+'H/QK<:^MEU!+!ID%T\33+%GYB@(!./3)'YTE!( MBEA*5)WBM3@O&'P^O_$'B&34;6Z@1)(U4K)G((&*P?\ A4FL?\_UK^;?X5ZC MK'B#2M!B234[V*V$AP@<\N?8=34FE:QIVMVGVK3;N*YASM+1MG!]#Z&ATXMW M)G@J4Y.36YYC9_"G5H;ZWF?4+<+'*KDJ6S@'/%>N5AIXQ\/2:O\ V4FJVQO- M_E",/U?^Z#TW>U;E.,5'8UHT(4K\G4**2BJ-A:*2B@!:*2B@!:*2B@!:*2B@ M!>HP:X[P\J_\+&\9?*./L../^F1KL*ABM+:&ZGNHH(TGN-OG2*N&DVC"Y/? MH XCQ,-5;XGZ&-'>S6Z_LN[R;L,4V^9#G[O.>E)X<&JK\4M7&LO9M=?V1;8- MH&";?-EQG=SG.?TKN&L[9[V.\:",W4:-&DI7YE5B"0#Z' _*A;.V6]>]6",7 M3QB)I@OS,@)(4GT!)_.@#S^$ZS_PL3Q;_94^EQIOM/,%ZK$D^0/NX[5K?$\Y M^&FK%-I.V+;Z$^:F/PK6U'PCX=U:]>\U#1;*YN7 #2RP@LP P,GZ5>.E:>VE MKIC64!L554%N4&P*N"!CVP* .)MEU34/B;I\.NQ6%E-IEM)=6GV4L_VL.#&X MW$# 3()7'4J:3QYJ%IJ6OV'ANZM+R\TZ-#>:E':6[RDCD0HVT' +9;G^X/6N M\EL[:>ZM[J6WC>XM]WDRLN6CW##8/;(ZTL5G;07-Q1I&"+@%F.6/U).: .+^(%O-:>&_#UM;2QF: M'5[&.*2XR5+!L OCMZUTVAG4_)E&J3:=)-N^3[$& "^^>^:LZEI=AK-F;34K M.&[MRP;RYD#+D=#@U6TKPWHNARR2:5I=K9O* KM#&%+ =C0!@>"KF"UU#Q?: MSRI%/'K4L[H[ $1O'&5?Z$ \^U2_#-IW*L/8CFM; M5O"F@:[X]CQ6M%''#$D42+'&BA51!@*!T '84 M>^_P"]CG[M='82:,;[43I[6GVI77[:8,;MV.-^ M.^/6G:OH6E:];K!JNGV]Y&AW()4!*GU!Z@_2I-,TK3]&LUM-,LH+2W!SY<*! M1GU..I]Z /-X)?\ A$=%L[BTN=,UWPFUZC0J5'VF%I)>"AY$A5FSV;\J]5K# >C\'^'(=7_M:/1+%+X-O$RP@$-_>';=[]:VZ /__9 end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 01, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 01, 2022
Entity Registrant Name CORTEXYME, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38890
Entity Tax Identification Number 90-1024039
Entity Address, Address Line One 601 Gateway Blvd
Entity Address, Address Line Two Ste 1250
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 415
Local Phone Number 910-5717
Entity Information, Former Legal or Registered Name Cortexyme, Inc.
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol CRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Current Fiscal Year End Date --12-31
Amendment Flag false
Entity Central Index Key 0001662774
XML 10 d346512d8k_htm.xml IDEA: XBRL DOCUMENT 0001662774 2022-08-01 2022-08-01 CORTEXYME, INC. --12-31 false 0001662774 8-K 2022-08-01 DE 001-38890 90-1024039 601 Gateway Blvd Ste 1250 South San Francisco CA 94080 415 910-5717 Cortexyme, Inc. false false false false Common Stock, $0.001 par value per share CRTX NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d346512d8k.htm crtx-20220801.xsd crtx-20220801_lab.xml crtx-20220801_pre.xml d346512dex31.htm d346512dex32.htm d346512dex991.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d346512d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d346512d8k.htm" ] }, "labelLink": { "local": [ "crtx-20220801_lab.xml" ] }, "presentationLink": { "local": [ "crtx-20220801_pre.xml" ] }, "schema": { "local": [ "crtx-20220801.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crtx", "nsuri": "http://www.cortexyme.com/20220801", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d346512d8k.htm", "contextRef": "duration_2022-08-01_to_2022-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d346512d8k.htm", "contextRef": "duration_2022-08-01_to_2022-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name", "terseLabel": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cortexyme.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001193125-22-207867-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-207867-xbrl.zip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Ɨ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end